Home
News
Intervet introduces new swine vaccine
Intervet/Schering-Plough Animal Health has announced
the introduction of Porcilis® COLI 6C, a swine vaccine against E. coli and
Clostridium perfringens.
The introduction of this swine vaccine enables Intervet/Schering-Plough
Animal Health to capitalise on its extensive expertise and years of technical
support in the E. coli and Clostridium perfringens markets, working with
veterinarians for the benefit of the swine industry.
Multivalent vaccine
formulationDr. Marc Dickie,
recently appointed as Head of the Global Swine business unit for
Intervet/Schering-Plough Animal Health, is excited about the introduction of
Porcilis® COLI 6C: “This product introduction enables our company to market the
multivalent vaccine formulation for control of E. coli and Clostridium
perfringens with 4 antigens of E. coli and toxoids from 3 strains of Clostridium
perfringens.
Moreover, we can market this vaccine in conjunction with
our monovalent E. coli vaccine, Porcilis® Porcoli DF. This offers veterinarians
and producers more options to choose the most appropriate vaccine for specific
enteric disease situations on each farm.â€
The new combination
Intervet/Schering-Plough Animal Health, resulting from Schering-Plough's
acquisition of the Intervet animal health business in October 2007, strengthens
the animal health portfolio in several areas and brings together complementary
lines of pharmaceuticals, biologicals and an enhanced science and technology
platform.
On-going commitmentThis ensures an on-going commitment to meet the challenges of
the various species segments. Intervet/Schering-Plough Animal Health is not only
the world market leader in the production of animal health vaccines, but is also
one of the world's leaders in the field of animal health.
Related
Website
•
Intervet
Schering-Plough Animal Health
Click here for
the free Pig Progress newsletter
Editor PigProgress
To comment, login here
Or register to be able to comment.